Ποια είναι η τιμή για Ensysce Biosciences, Inc. (ENSC)

Η τιμή για Ensysce Biosciences, Inc. (ENSC) είναι $0.5275

Ποια είναι η κεφαλαιοποίηση αγοράς για Ensysce Biosciences, Inc. (ENSC)

Η κεφαλαιοποίηση αγοράς για Ensysce Biosciences, Inc. (ENSC) είναι $1.25M

Ensysce Biosciences, Inc. (ENSC) Μετοχές σε Κυκλοφορία

Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid addiction, misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP prodrug candidate of oxycodone, which is in Phase II clinical trial for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat that is in Phase I clinical trial for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF329, an extended-release prodrug of hydromorphone that is similar to PF614; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD medication abuse; and PF26810, an extended-release prodrug of methadone for opioid use disorder. The company is based in La Jolla, California.

Έτος	Κυκλοφορούντες μετοχές	Αλλαγή
2026 (TTM)	2.89M	65.20%
2024	1.75M	-22.84%
2023	2.26M	1,158.25%
2022	179.93K	114.16%
2021	84.02K	-98.12%
2020	4.46M	-26.81%
2019	6.09M	1.42%
2018	6.01M	0.37%
2017	5.98M	0.00%

Έτος

Κυκλοφορούντες μετοχές

Αλλαγή

2026 (TTM)

2.89M

65.20%

2024

1.75M

-22.84%

2023

2.26M

1,158.25%

2022

179.93K

114.16%

2021

84.02K

-98.12%

2020

4.46M

-26.81%

2019

6.09M

1.42%

2018

6.01M

0.37%

2017

5.98M

0.00%

Εταιρεία	Κυκλοφορούντες μετοχές	Διαφορά	Χώρα
Novo Nordisk A/S NVO.US	4.45B	154,015.04%	DK
Vertex Pharmaceuticals Incorporated VRTX.US	253.90M	8,697.46%	US
Regeneron Pharmaceuticals, Inc. REGN.US	102.90M	3,465.42%	US
UCB SA UCB.BR	190.00M	6,483.27%	BE
CSL Limited CSL.AX	483.58M	16,655.56%	AU

Εταιρεία

Κυκλοφορούντες μετοχές

Διαφορά

Χώρα